Variability of adenovirus receptor density influences gene transfer efficiency and therapeutic response in head and neck cancer
- PMID: 10632357
Variability of adenovirus receptor density influences gene transfer efficiency and therapeutic response in head and neck cancer
Abstract
Despite encouraging preclinical studies in many tumor types including head and neck squamous cell carcinoma (HNSCC), initial clinical trials with adenovirus-mediated gene therapy have been disappointing. Although the adenovirus is a "highly efficient vector," it is still limited by the extent of effective in vivo transduction. In our studies with multiple human HNSCC cell lines, we have noted a variation in both in vitro and in vivo responses to the same recombinant adenovirus therapeutic construct. We hypothesize that adenovirus receptor density among tumor cell populations, even of the same histology, greatly influences transduction efficiency and therapeutic results of a variety of adenovirus-based gene therapy strategies. To investigate this hypothesis, the numbers of adenovirus receptors on three well-characterized HNSCC cell lines were determined. Marker and cytokine gene transfer efficiencies as well as therapeutic outcomes after adenovirus-mediated tumor suppressor gene and suicide gene therapies were evaluated and correlated with receptor status. A 5-fold variation in adenovirus receptor density was identified among the HNSCC cell lines (P < 0.002, t test). This variation directly correlated with adenovirus type 5 (Ad5)-mediated green fluorescent protein marker gene and Ad5-interleukin 2 cytokine gene transfer efficiency and resulting protein expression in each individual cell line. The receptor density also directly correlated with therapeutic response after Ad5-thymidine kinase or Ad5-p16 gene transfer in each HNSCC line. The role of the adenovirus receptor in gene transfer efficiency was further supported by recombinant Ad5 fiber knob blocking experiments. The marker gene transfer was increasingly blocked by the same concentration of Ad5 recombinant fiber knob in relation to decreasing levels of adenovirus receptor in the HNSCC lines. An Ad5 recombinant construct that carries the shared coxsackie and adenovirus receptor (CAR) was created and used to up-regulate receptors on each cell line. Ad5-CAR infection significantly increased Ad5-beta-Gal gene transfer efficiency and expression (P = 0.0003, Mann-Whitney test). This increased marker gene expression remained consistent with the established pattern of gene transfer efficiency among the HNSCC cell lines. These data confirm the importance of the adenovirus receptor on individual tumor cell lines with respect to investigating novel adenovirus-mediated gene therapy strategies. This work further supports consideration of assaying adenovirus receptor status, even in tumors of the same histology from patients enrolled in gene therapy clinical trials. Adenovirus receptor status may prove valuable for selecting or stratifying patients as well as assessing outcomes among patients within adenovirus-based cancer gene therapy trials.
Similar articles
-
Novel adenoviral gene delivery system targeted against head and neck cancer.Laryngoscope. 2008 Apr;118(4):650-8. doi: 10.1097/MLG.0b013e3181613aba. Laryngoscope. 2008. PMID: 18176343
-
Head and neck cancer cells are efficiently infected by Ad5/35 hybrid virus.J Gene Med. 2006 Oct;8(10):1223-31. doi: 10.1002/jgm.957. J Gene Med. 2006. PMID: 16941521
-
p16INK4A adenovirus-mediated gene therapy for human head and neck squamous cell cancer.Clin Cancer Res. 1998 Jul;4(7):1697-704. Clin Cancer Res. 1998. PMID: 9676844
-
[Somatic gene therapy in squamous epithelial carcinomas of the head-neck area].Laryngorhinootologie. 1996 Jun;75(6):356-62. doi: 10.1055/s-2007-997594. Laryngorhinootologie. 1996. PMID: 8766383 Review. German.
-
Cancer-targeting gene therapy using tropism-modified adenovirus.Anticancer Res. 2007 Nov-Dec;27(6A):3679-84. Anticancer Res. 2007. PMID: 17970028 Review.
Cited by
-
Adenoviral gene delivery to solid tumors by recombinant silk-elastinlike protein polymers.Pharm Res. 2007 Apr;24(4):773-9. doi: 10.1007/s11095-006-9200-5. Epub 2007 Feb 17. Pharm Res. 2007. PMID: 17308969
-
An oncolytic virus as a promising candidate for the treatment of radioresistant oral squamous cell carcinoma.Mol Ther Oncolytics. 2022 Oct 8;27:141-156. doi: 10.1016/j.omto.2022.10.001. eCollection 2022 Dec 15. Mol Ther Oncolytics. 2022. PMID: 36381653 Free PMC article.
-
A novel adenoviral vector labeled with superparamagnetic iron oxide nanoparticles for real-time tracking of viral delivery.J Clin Neurosci. 2012 Jun;19(6):875-80. doi: 10.1016/j.jocn.2011.12.016. Epub 2012 Apr 18. J Clin Neurosci. 2012. PMID: 22516547 Free PMC article.
-
A systematic approach to virus-virus interactions.Virus Res. 2010 Apr;149(1):1-9. doi: 10.1016/j.virusres.2010.01.002. Epub 2010 Jan 20. Virus Res. 2010. PMID: 20093154 Free PMC article. Review.
-
Poliovirus receptor CD155-targeted oncolysis of glioma.Neuro Oncol. 2004 Jul;6(3):208-17. doi: 10.1215/S1152851703000577. Neuro Oncol. 2004. PMID: 15279713 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical